Trevi Therapeutics/$TRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
$TRVI
Sector
Primary listing
Employees
33
Headquarters
Website
TRVI Metrics
BasicAdvanced
$1.2B
-
-$0.42
0.59
-
Price and volume
Market cap
$1.2B
Beta
0.59
52-week high
$10.16
52-week low
$2.36
Average daily volume
2.5M
Financial strength
Current ratio
22.425
Quick ratio
22.153
Long term debt to equity
0.305
Total debt to equity
0.449
Interest coverage (TTM)
-25,760.50%
Profitability
EBITDA (TTM)
-51.372
Effective tax rate (TTM)
0.10%
Management effectiveness
Return on assets (TTM)
-22.83%
Return on equity (TTM)
-35.74%
Valuation
Price to book
6.13
Price to tangible book (TTM)
6.13
Price to free cash flow (TTM)
-26.639
Free cash flow yield (TTM)
-3.75%
Free cash flow per share (TTM)
-0.375
Growth
Earnings per share change (TTM)
6.99%
3-year earnings per share growth (CAGR)
-22.00%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
Bulls say / Bears say
Topline data from the Phase 2b CORAL trial showed Haduvio achieved up to a 60.2% reduction in 24-hour cough frequency at the 108 mg BID dose (p<0.0001), meeting the primary endpoint across all dose groups (Trevi Therapeutics IR)
Additional analyses from the Phase 2a RIVER trial demonstrated statistically significant responder rates at 30%, 50%, and 75% thresholds and improvements in the Leicester Cough Questionnaire, reinforcing Haduvio’s consistent efficacy across multiple endpoints (p<0.0001) (Trevi Therapeutics IR)
In Q2 2025, Trevi closed a $115.1 million underwritten offering, bolstering its balance sheet and providing an expected cash runway into 2029 to fund ongoing development of Haduvio (PR Newswire)
Phase 3 pivotal trials are not expected to begin until the first half of 2026, delaying potential regulatory approval and commercial launch by at least 18 months (Trevi Therapeutics IR)
As of Q1 2025, Trevi held $103.3 million in cash with a runway only through Q4 2026, raising the risk of further dilutive financing before Haduvio could reach commercialization (Trevi Therapeutics IR)
In the Phase 2b CORAL trial, common adverse events—including nausea, vomiting, constipation, dizziness, headache, and fatigue—were reported, which could limit patient tolerability and adherence (Trevi Therapeutics IR)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $1.2B as of October 12, 2025.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of October 12, 2025.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.